BMY Bristol-Myers Squibb Earnings and EPS analysis

Relative Growth: Rel. Growth:

Relative Strength: Rel. Strength:

Relative Valuation: Rel. Valuation:

Relative Profitability: Rel. Profitability: 95

EPS in 2026 (TTM): $4.53

Last Report Period Date: Sep 30, 2026

According to the most recent financial data from September 2026, the current EPS (TTM) is $4.53. Bristol-Myers Squibb's EPS for 2025 came in at $3.47, marking an increase from -$4.41 in 2024. For the quarterly period ending on Sep 30, 2026, BMY's EPS was $1.06.

BMY earnings history

Historical annual and quarterly earnings per share (EPS) data for Bristol-Myers Squibb

EPS (TTM)

$4.53

EPS Growth YoY (Quarterly)

-1.9%

EPS (Quarterly)

$1.06

EPS Growth (Quarterly)

-34.6%

Bristol-Myers Squibb had an annual EPS of $3.47, marking an increase of 178.7% from -$4.41 in 2024. The quarterly EPS for the period ending Sep 30, 2026, was $1.06, marking a 1.9% decrease from the same quarter last year. BMY's TTM EPS stands at $4.53 as of September 2026. Bristol-Myers Squibb's EPS for 2024 stood at -$4.41, a 213.7% decrease from 2023.

BMY EPS vs price chart

BMY EPS growth history

Earnings per share growth rates over time

EPS Growth YoY (Quarterly)

-1.9%

EPS growth YoY

178.7%

EPS growth 3Y avg

5.3%

EPS growth 5Y avg

N/A

Bristol-Myers Squibb has recorded a decrease in EPS of 1.9% over the last 12 months (YoY, quarterly). For the last three years, BMY recorded an average annual EPS growth rate of 5.3%. Across the last decade, BMY had an average annual EPS growth of 14%.

BMY Earnings Waterfall

Breakdown of revenue, profit and net income for Bristol-Myers Squibb

BMY Earnings vs Peers

What are the earnings of BMY compared to its peers

Stock name	Price to Earnings	EPS grwoth 1Y	EPS grwoth 3Y	EPS grwoth 5Y
BMY Bristol-Myers Squibb Company	13.85	178.7%	5.3%	N/A
AZN Astrazeneca plc	25.96	45.4%	46%	22%
AMGN AMGEN Inc	26.92	88.1%	5.6%	2.9%
NVS Novartis AG	30.51	21.8%	31.2%	15.2%
ABT Abbott Laboratories	39.79	-51.4%	-1.8%	8.2%
PFE Pfizer Inc	40.86	-3.5%	-37.4%	-3.7%
JNJ Johnson & Johnson	42.62	90.6%	17.7%	14.8%
LLY Lilly(Eli) & Company	46.57	95.6%	49.2%	27.5%
ABBV Abbvie Inc	50.71	-1.3%	-29.1%	-2.8%
MRK Merck & Co Inc	147.68	8%	8.4%	21.2%

All data is based on quarterly TTM periods, unless otherwise specified.